ER-HER2 receptor bidirectional molecular pathway cross-talk has been largely reported in the context of endocrine or anti-HER2 therapy resistance in hormone receptor (HR) and HER2-positive breast cancer [48]. This evidence concerns the gene NR4A1 and breast cancer.